Rep. Thomas H. Kean Jr. (R-NJ) supports an amendment to a provision of the Inflation Reduction Act, which would equalize the exemption period on price negotiation for both biologic and small-molecule drugs, and thereby provide a more level playing field for pharmaceutical innovation.
